Melanoma
"Melanoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Descriptor ID |
D008545
|
MeSH Number(s) |
C04.557.465.625.650.510 C04.557.580.625.650.510 C04.557.665.510
|
Concept/Terms |
Melanoma- Melanoma
- Melanomas
- Malignant Melanoma
- Malignant Melanomas
- Melanoma, Malignant
- Melanomas, Malignant
|
Below are MeSH descriptors whose meaning is more general than "Melanoma".
Below are MeSH descriptors whose meaning is more specific than "Melanoma".
This graph shows the total number of publications written about "Melanoma" by people in this website by year, and whether "Melanoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 6 | 0 | 6 | 1996 | 3 | 0 | 3 | 1997 | 5 | 1 | 6 | 1998 | 4 | 0 | 4 | 1999 | 4 | 0 | 4 | 2000 | 5 | 2 | 7 | 2001 | 5 | 1 | 6 | 2002 | 5 | 2 | 7 | 2003 | 5 | 2 | 7 | 2004 | 4 | 0 | 4 | 2005 | 13 | 1 | 14 | 2006 | 12 | 1 | 13 | 2007 | 6 | 1 | 7 | 2008 | 12 | 2 | 14 | 2009 | 15 | 1 | 16 | 2010 | 6 | 2 | 8 | 2011 | 15 | 2 | 17 | 2012 | 16 | 2 | 18 | 2013 | 23 | 5 | 28 | 2014 | 22 | 2 | 24 | 2015 | 14 | 6 | 20 | 2016 | 23 | 2 | 25 | 2017 | 30 | 0 | 30 | 2018 | 23 | 2 | 25 | 2019 | 18 | 3 | 21 | 2020 | 25 | 2 | 27 | 2021 | 20 | 0 | 20 | 2022 | 16 | 0 | 16 | 2023 | 15 | 0 | 15 | 2024 | 19 | 2 | 21 | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Melanoma" by people in Profiles.
-
Borgers JSW, Lenkala D, Kohler V, Jackson EK, Linssen MD, Hymson S, McCarthy B, O'Reilly Cosgrove E, Balogh KN, Esaulova E, Starr K, Ware Y, Klobuch S, Sciuto T, Chen X, Mahimkar G, Sheen JHF, Ramesh S, Wilgenhof S, van Thienen JV, Scheiner KC, Jedema I, Rooney M, Dong JZ, Srouji JR, Juneja VR, Arieta CM, Nuijen B, Gottstein C, Finney OC, Manson K, Nijenhuis CM, Gaynor RB, DeMario M, Haanen JB, van Buuren MM. Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial. Nat Med. 2025 Mar; 31(3):881-893.
-
Webster J, Ghith J, Penner O, Lieu CH, Schijvenaars BJA. Using Artificial Intelligence to Support Informed Decision-Making on BRAF Mutation Testing. JCO Precis Oncol. 2024 Oct; 8:e2300685.
-
Yee EJ, Thielen ON, Truong R, Gilbert D, Michel K, Couts KL, Robinson WA, McCarter MD. Metastatic Melanoma to the Small Bowel and Colon: A Systematic Review of the Global Experience and Institutional Cohort Analysis Detailing a Rare Clinical Entity. J Surg Oncol. 2025 Mar; 131(4):671-684.
-
Nielsen AJ, Albert GK, Sanchez A, Chen J, Liu J, Davalos AS, Geng D, Bradeen X, Hintzsche JD, Robinson W, McCarter M, Amato C, Tobin R, Couts K, Wilky BA, Davila E. DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. J Clin Invest. 2024 Oct 22; 134(24).
-
Aloy NM, Coughlan C, Graner MW, Witt SN. Possible regulation of the immune modulator tetraspanin CD81 by alpha-synuclein in melanoma. Biochem Biophys Res Commun. 2024 11 19; 734:150631.
-
Dravillas CE, Coleman SS, Hoyd R, Caryotakis G, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC. The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. Cancer Res Commun. 2024 08 01; 4(8):1978-1990.
-
Oatman N, Gawali MV, Congrove S, C?ceres R, Sukumaran A, Gupta N, Murugesan N, Arora P, Subramanian S, Choi K, Abdel-Malek Z, Reisz JA, Stephenson D, Amaravadi R, Desai P, D'Alessandro A, Komurov K, Dasgupta B. A Multimodal Drug-Diet-Immunotherapy Combination Restrains Melanoma Progression and Metastasis. Cancer Res. 2024 Jul 15; 84(14):2333-2351.
-
Turner JA, Van Gulick RJ, Robinson WA, Mughal T, Tobin RP, MacBeth ML, Holman B, Classon A, Bagby SM, Yacob BW, Hartman SJ, Silverman I, Vorwald VM, Gorden N, Gonzalez R, Gay LM, Ali SM, Benson A, Miller VA, Ross JS, Pitts TM, Rioth MJ, Lewis KD, Medina T, McCarter MD, Gonzalez R, Couts KL. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling. Int J Cancer. 2024 Nov 15; 155(10):1792-1807.
-
Qiao Z, Xu J, Gallazzi F, Fisher DR, Gonzalez R, Kwak J, Miao Y. Effect of Ibuprofen as an Albumin Binder on Melanoma-Targeting Properties of 177Lu-Labeled Ibuprofen-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. Mol Pharm. 2024 Aug 05; 21(8):4004-4011.
-
Rosenberg SA. Lymphocytes as a living drug for cancer. Science. 2024 07 05; 385(6704):25-26.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|